Effect of recombinant human erythropoietin after allogenic bone marrow transplantation.
The hematologic effects of recombinant human erythropoietin after allogeneic bone marrow transplantation (BMT) were studied. Nineteen patients received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion until hematocrit exceeded 35%. These data were compared with a treatment-matched historical control group of 43 patients. RHu EPO-treated patients recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.
Link
H
H
Interdisciplinary Unit for Bone Marrow Transplantation, Medical School, Hannover, Germany.
Brune
T
T
Hübner
G
G
Diedrich
H
H
Freund
M
M
Stoll
M
M
Peest
D
D
Ebell
W
W
Bettoni
C
C
Oster
W
W
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D017707:Erythrocyte Transfusion; D004920:Erythropoiesis / Q000187:drug effects / Q000502:physiology; D004921:Erythropoietin / Q000097:blood / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000097:blood / Q000494:pharmacology / Q000633:toxicity
D011994:Recombinant Proteins; D004921:Erythropoietin